Rayburn West Financial Services LLC Makes New $1.18 Million Investment in Pfizer Inc. $PFE

Rayburn West Financial Services LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel reports. The fund purchased 47,530 shares of the biopharmaceutical company’s stock, valued at approximately $1,183,000.

A number of other large investors have also bought and sold shares of the stock. Triad Wealth Partners LLC increased its stake in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares during the period. ETF Store Inc. increased its stake in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the period. Mattern Wealth Management LLC increased its stake in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. Pines Wealth Management LLC increased its stake in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 400 shares during the period. Finally, Quest Investment Management LLC increased its stake in shares of Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 405 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.3%

NYSE PFE opened at $25.96 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $21.97 and a twelve month high of $28.75. The firm has a market capitalization of $147.93 billion, a PE ratio of 19.81 and a beta of 0.35. The stock’s 50 day moving average is $27.03 and its 200 day moving average is $26.19.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the company posted $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. UBS Group boosted their target price on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Monday, April 13th. Finally, Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.74.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A and B patients with inhibitors, a label expansion that could help broaden future sales. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
• Positive Sentiment: Analyst coverage highlighted Pfizer’s rebound story, with the company targeting high-single-digit revenue CAGR from 2029 as new launches, acquisitions, and pipeline growth may offset patent-expiration headwinds. Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
• Positive Sentiment: Multiple market commentators argued Pfizer looks undervalued after recent earnings, with some calling it a possible long-term buying opportunity and noting healthy underlying results despite a muted reaction. Top Analyst Reports for Meta, Pfizer & Salesforce
• Neutral Sentiment: Pfizer and partner Arvinas licensed VEPPANU (vepdegestrant) rights to Rigel Pharmaceuticals, bringing Pfizer $85 million in upfront and transition payments plus potential milestones and royalties, but also ceding commercialization control. Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
• Negative Sentiment: Bearish commentary continued to focus on Pfizer’s post-pandemic slowdown, with articles questioning dividend sustainability and whether the company can regain stronger growth as older products face loss of exclusivity. Pfizer’s Net Income Drops in Q1. Is Its Dividend Still Safe?
• Negative Sentiment: Broader sector coverage also pointed to tougher vaccine demand conditions in the U.S., which could weigh on sentiment toward large pharma names including Pfizer. How tough is it getting for vaccine makers in the U.S.?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.